FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.
What happened
FDA inspected Daewoo Pharmaceutical's Busan drug manufacturing facility from January 6 to 15, 2025. FDA found significant CGMP (manufacturing quality rules) violations in sterile aseptic processing, including inadequate smoke studies and media fills, poor aseptic practices, insufficient environmental and personnel monitoring, visual inspection failures, quality-unit and investigation problems, and inadequate raw-material and cleaning controls. FDA reviewed the company's February 12, 2025 response and found it inadequate; the company also said it suspended all drug production and deregistered the facility as a drug manufacturer.
What FDA found
The company did not properly control aseptic (sterile) processing: smoke studies showed turbulent airflow, media fills did not simulate commercial production, operators used poor practices in the ISO 5 critical area, and personnel monitoring was insufficient.
21 CFR 211.113(b)The aseptic filling line design and equipment controls were inadequate, and equipment that contacts primary containers and closures was disinfected but not sterilized.
21 CFR 211.42(c)(10)The company's visual inspection program was inadequate to detect visible defects and particulates, and it lacked appropriate inspector qualification.
21 CFR 211.100(a)The quality control unit did not provide adequate oversight, and written procedures for critical aseptic operations were missing or incomplete.
21 CFR 211.22; 21 CFR 211.100Investigations and complaint handling were inadequate, including failure to investigate a mold trend and to test retain samples for sterility promptly, and raw-material testing for a high-risk contaminant was insufficient.
21 CFR 211.192; 21 CFR 211.198(a); 21 CFR 211.84(d)(2)Cleaning and disinfection procedures for equipment were not detailed or repeatable, and disinfection efficacy and room decontamination validation were deficient.
21 CFR 211.67(b)
What FDA wants
FDA tells Daewoo to respond in writing within 15 working days with corrective actions and preventive actions, including risk assessments and remediation plans for aseptic processing, environmental monitoring, visual inspection, quality systems, raw-material testing, and cleaning. FDA also asks the company to clarify whether it intends to resume U.S. drug manufacturing and to notify FDA before resuming.
Who should pay attention
- US distributors and importers of Daewoo drug products
- companies that buy or use Daewoo-made drugs
- sterile drug manufacturers with aseptic filling operations
This is a summary. Read the original letter on fda.gov.